- Entry
- $1.31
- Now
- $1.40 +6.9%
- Target
- —
- Score
- —
I have been searching for small oncology companies with the potential to experience the kind of revaluation that occurs when convincing clinical data finally attracts market attention. **MAIA Biotechnology ($MAIA)** may be one of the more interesting examples I have found. MAIA currently trades around **$1.33**, giving it a market capitalization of approximately **$80 million** with 60.8 million shares outstanding. This remains a tiny valuation for a company that already has a randomized Phase 3 cancer trial underway. ([Current market …
— ORIGINAL POST ·
$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne
· r/pennystocks
· Sep 8, 2026